A seed-stage therapeutics company based in Tufts Biolabs, Boston MA, management of AXONIS Therapeutics indicate theirdeclared objective of making a real difference for patients, their families, and the global healthcare system. The firm's efforts arestructured around breakthrough drug discoveries to develop first-in-class therapies for currently incurable neurological disorders. Adult-onset central nervous system (CNS) disorders are an urgent, unmet, global and growing burden, especially as more people are living longer. Neuron degeneration and excitation/inhibition imbalances are fundamental problems of many debilitating neurological disorders. AXONIS is developing a pipeline of neuron-reviving therapeutics which enable an intrinsic ability of CNS neurons to: (1) resist neurodegeneration, (2) restore excitation/inhibition balance, and (3) regenerate.
